 |
市場調查報告書
商品編碼
1524289
耐甲氧西林金黃色葡萄球菌藥物市場 - 按藥物類別（糖肽）、MRSA 類型（醫院獲得性、社區獲得性）、給藥途徑、適應症（菌血症）、配銷通路- 全球預測（2024 - 2032）Methicillin-resistant Staphylococcus Aureus Drugs Market - By Drug Class (Glycopeptides), MRSA Type (Hospital-acquired, Community-acquired), Route of Administration, Indication (Bacteraemia), Distribution Channel - Global Forecast (2024 - 2032) |
||||||
由於抗生素誘導的金黃色葡萄球菌菌株引發的持續挑戰，2024 年至 2032 年間，全球耐甲氧西林金黃色葡萄球菌藥物市場規模將達到 4.2% 的複合年成長率。傳統抗生素對抗甲氧西林金黃色葡萄球菌 MRSA 無效，迫切需要新的治療方案。
製藥公司、研究機構和政府機構也在加緊努力開發新藥、疫苗和治療策略來對抗 MRSA 感染。例如，2023 年 12 月，科學家利用更透明的深度學習模式發現了一類針對抗藥性金黃色葡萄球菌的新型抗生素。基因組學、免疫學和藥物發現機制的進步也為 MRSA 感染的發病機制和潛在的治療標靶提供了新的見解，強調了急診醫學的重要性。對 RampD 的日益關注將推動創新並塑造 MRSA 治療的未來。
整個產業分為藥品類別、MRSA類型、給藥途徑、適應症、配銷通路和地區。
根據藥物類別，脂肽領域的抗甲氧西林金黃色葡萄球菌藥物產業將在2024年至2032年經歷嚴格的發展。活性而聞名。由於 MRSA 菌株對傳統抗生素的反應較差，脂肽因其獨特的作用機制和低抗藥性而提供了有價值的替代品。一些製藥公司也專注於開發和銷售以脂肽為基礎的藥物，以應對日益成長的 MRSA 感染威脅。
根據MRSA類型，來自社區獲得的CA-MRSA細分市場的耐甲氧西林金黃色葡萄球菌藥物市場將在2024年至2032年出現顯著的複合年成長率。 ，對公共衛生造成嚴重影響憂慮。 CA-MRSA 菌株能夠在健康個體中引起嚴重感染，導致對有效治療的需求不斷增加。製藥公司也正在關注針對 CA-MRSA 菌株的藥物，以應對這一日益嚴重的威脅。
由於對有效治療的需求不斷增加，2024年至2032年歐洲耐甲氧西林金黃色葡萄球菌藥物市場將呈現出值得稱讚的複合年成長率。隨著醫療保健相關和社區獲得性 MRSA 感染發生率的不斷增加，該地區迫切需要新的抗生素。製藥公司也正在投資 RampD 活動來滿足這項需求，同時推出新藥來對抗歐洲 MRSA 菌株的流行。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- MRSA 感染發生率增加
- 抗生素抗藥性不斷增強
- 藥物開發的進展
- 產業陷阱與挑戰
- 治療費用高
- 成長動力
- 成長潛力分析
- 管道分析
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年
- 主要趨勢
- 醣肽類
- 脂肽
- 噁唑烷酮類
- 頭孢菌素
- 四環素
- 葉酸拮抗劑
- 其他藥物類別
第 6 章：市場估計與預測：按 MRSA 類型，2021 - 2032 年
- 主要趨勢
- 醫院獲得性 (HA-MRSA)
- 社區型 (CA-MRSA)
第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年
- 主要趨勢
- 口服
- 注射用
第 8 章：市場估計與預測：按指標分類，2021 - 2032 年
- 主要趨勢
- 皮膚和軟組織感染
- 骨骼和關節感染
- 呼吸道感染
- 菌血症
- 其他適應症
第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 網路藥局
第 10 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 11 章：公司簡介
- AbbVie Inc.
- Basilea Pharmaceutica Ltd
- Baxter International Inc.
- Cumberland Pharmaceuticals Inc.
- GlaxoSmithKline plc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Global Methicillin-resistant Staphylococcus Aureus Drugs Market size will witness 4.2% CAGR between 2024 and 2032 owing to ongoing challenges, triggered by antibiotic-induced Staphylococcus aureus strains. Conventional antibiotics against methicillin-resistant staphylococcus aureus MRSA are ineffective, and new treatment options are critically needed.
Pharmaceutical companies, research institutes, and government agencies are also intensifying their efforts to develop new drugs, vaccines, and therapeutic strategies to combat MRSA infections. For instance, in December 2023, scientists discovered a new class of antibiotics for drug-resistant Staphylococcus aureus bacteria from the utilization of more transparent deep learning models. Advances in genomics, immunology, and drug discovery mechanisms are also providing new insights into the pathogenesis of MRSA infections and potential therapeutic targets for emphasizing the importance of emergency medicine. This increased focus on R&D is poised to drive innovations and shape the future of MRSA treatments.
The overall industry is classified into drug class, MRSA type, route of administration, indication, distribution channel and region.
According to drug class, the methicillin-resistant staphylococcus aureus drugs industry from the lipopeptides segment will undergo rigorous development from 2024 to 2032. Lipopeptides are promising antimicrobial agents, known for their potent activity against MRSA and other drug-resistant bacteria. As MRSA strains are poorly responsive to conventional antibiotics, lipopeptides offer valuable alternatives due to their unique mechanism of action and low resistance. Several pharmaceutical companies are also focusing on developing and marketing lipopeptide-based drugs to combat the growing threat of MRSA infections.
On the basis of MRSA type, the methicillin-resistant staphylococcus aureus drugs market from the community acquired CA-MRSA segment will register notable CAGR from 2024 to 2032. This is due to the rise in CA-MRSA infections, which pose a serious public health concern. The ability of CA-MRSA strains to cause serious infections in otherwise healthy individuals, has led to the increasing demand for effective treatment. Pharmaceutical companies are also focusing on drugs targeting CA-MRSA strains to combat this growing threat.
Europe methicillin-resistant staphylococcus aureus drugs market will showcase a commendable CAGR from 2024 to 2032 due to the increasing need for effective treatments. With the increasing incidence of healthcare-associated and community-acquired MRSA infections, new antibiotics are urgently required in the region. Pharmaceutical companies are also investing in R&D activities to meet this demand while introducing new drugs to combat the prevalence of MRSA strains in Europe.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing incidence of MRSA infections
- 3.2.1.2 Growing antibiotic resistance
- 3.2.1.3 Advancements in drug development
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of therapeutics
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Pipeline analysis
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Glycopeptides
- 5.3 Lipopeptides
- 5.4 Oxazolidinones
- 5.5 Cephalosporin
- 5.6 Tetracycline
- 5.7 Folate antagonist
- 5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By MRSA Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Hospital-acquired (HA-MRSA)
- 6.3 Community-acquired (CA-MRSA)
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Skin and soft tissue infections
- 8.3 Bone & joint infections
- 8.4 Respiratory infections
- 8.5 Bacteremia
- 8.6 Other indications
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Hospital pharmacies
- 9.3 Retail pharmacies
- 9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
- 11.1 AbbVie Inc.
- 11.2 Basilea Pharmaceutica Ltd
- 11.3 Baxter International Inc.
- 11.4 Cumberland Pharmaceuticals Inc.
- 11.5 GlaxoSmithKline plc.
- 11.6 Johnson & Johnson
- 11.7 Merck & Co., Inc.
- 11.8 Novartis AG
- 11.9 Pfizer Inc.
- 11.10 Teva Pharmaceutical Industries Ltd.
